Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756611 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
NCT02756611 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 258 participants.
The verdict
NCT02756611, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment with a B-cell receptor inhibitor.
Interventions
- DRUG Venetoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756611
The ClinicalTrials.gov registry entry for NCT02756611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Venetoclax is the first listed.
NCT02756611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756611 about?
NCT02756611 is a clinical study titled "A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment with a B-cell receptor inhibitor.
What is the current status of trial NCT02756611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2016-06-22. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT02756611?
The interventions under investigation include: Venetoclax (DRUG).
Who is sponsoring clinical trial NCT02756611?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.